Products
Online Inquiry
Binimetinib
Cat. No.:
0225LY-0526
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Binimetinib is an orally active, selective MEK1/2 inhibitor (IC50 = 12 nM) used to treat metastatic melanoma characterized by BRAF V600K or V600E mutations.
Synonym:
ARRY-438162; ARRY-162; MEK162; 606143-89-9; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; 6-(4-Bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aa,5a,6aa)-octahydro- 2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-
CAS No.:
606143-89-9
Compound CID:
10288191
Formula:
C17H15BrF2N4O3
Formula Weight:
441.23
Specification
Targets&IC50:
MEK: 12 nM
Relative Density:
1.67 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Binimetinib can be used in MAPK pathway research to explore the specific inhibition of MEK1 and MEK2 in various malignancies.
Library Information
Target:
MEK
Receptor:
MEK
Pathways:
Autophagy; MAPK
Plate Number:
AOCL-7
Plate Location:
g9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 113.32 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL
